AI in Cardiology: Why Better Detection Has Not Yet Meant Better Outcomes
- AI models match or exceed specialist accuracy on ECG interpretation, imaging analysis and risk scoring in retrospective studies.
- Prospective evidence is scarce, and the few randomized trials measure diagnosis rates more often than clinical outcomes.
- Detection changes nothing when no defined action follows, and most deployed tools stop at the alert.
- Training data drawn overwhelmingly from high-income countries limits how well models transfer to other populations.
- Integration with hospital records, clinician trust and reimbursement decide adoption more than model performance does.
- Aegis Capital backs early-stage companies whose technology has a clinical pathway attached, not only a validation metric.
Artificial intelligence AI in cardiology: what the evidence shows
The use of artificial intelligence in this field is not new, since automated ECG interpretation has been available in hospitals for decades, however the recent generation of models infers far more from the same recording. Cardiology generates the kind of data machine learning handles well: waveforms, images and dense time series produced in enormous volume. Models trained on millions of ECGs detect atrial fibrillation in sinus rhythm, estimate ejection fraction, flag valvular disease with high sensitivity and score the risk of adverse cardiac events from routine records. Mayo Clinic research on AI-enabled ECG has been central to this work, and its EAGLE trial, published in Nature Medicine in 2021, remains one of the few pragmatic randomized studies in the area; it increased the rate at which low ejection fraction was newly diagnosed in primary care.
The evidence stops in a specific place. Increased diagnosis is a process measure, not a health outcome, and a JACC state-of-the-art review of machine learning in cardiovascular medicine makes the same point about the wider literature: most published models report discrimination statistics from retrospective datasets, and external validation in a different hospital usually degrades them.
What AI can detect in ECG and imaging
Detection performance is the strong part of the story, and three capabilities are well documented:
- ECG analysis at expert level, including rhythm classification and structural inference that human readers cannot perform from the same signal.
- Echocardiographic and MRI measurement, where automated segmentation reduces the variability between operators.
- Continuous monitoring, since consumer and medical wearables track heart rhythm around the clock and algorithms process the resulting beats in near real time.
AI has the potential to function as a second reader in each of these tasks, and community hospitals without a resident specialist stand to gain most, for example where an echocardiogram would otherwise wait days for interpretation. In addition, models built on electronic records estimate the risk of myocardial infarction and readmission from variables clinicians already collect. AI can also compress time in emergencies, prioritizing a study for immediate review instead of leaving it in a queue.
Early detection of heart failure and arrhythmia
Heart failure illustrates both the promise and the problem. Algorithms identify reduced ejection fraction and predict decompensation weeks before admission, which offers a real window for intervention. Whether that window gets used depends on what the health system does next.
An alert delivered to a busy clinic without a defined pathway produces a decision no one owns. The patient needs an echocardiogram, a medication review, a follow-up appointment and someone accountable for arranging all three; a flag in a chart arranges none of it. Another condition applies: the output has to reach the person making the decision while the window is still open. Programs that show outcome benefit tend to pair the model with a nurse-led or pharmacist-led protocol, and the protocol does much of the work. According to the teams that run them, the protocol does more for outcomes than the algorithm does.
The limits of AI in cardiology outside the study population
Model performance depends on who appears in the training data. More than 80% of participants in genome-wide association studies have been of European ancestry, and cardiovascular datasets show a similar skew: most data comes from health systems in the United States and Europe. AI systems trained on that material can misclassify patients whose physiology, disease prevalence or care patterns differ.
A warning circulating in policy discussion says AI could exclude five billion people from healthcare. Read literally that claim overstates the mechanism, since the five billion figure describes people who already lack access to safe surgical and diagnostic care. The realistic risk is narrower and still serious: tools validated on data from high-income settings enter markets that never contributed to their development, and errors there stay invisible because no local evaluation exists. Diverse data collection is the critical step, and scientific groups have begun publishing external validations that show how far performance drops outside the original population.
Overdiagnosis and the cost of finding more
Sensitivity has a downside that detection metrics do not capture. Screening asymptomatic people with a very sensitive algorithm surfaces minor abnormalities that would never have caused harm, and each finding starts a cascade. Three consequences recur:
- Medication started for a finding that would have resolved without treatment.
- Invasive follow-up, including catheterization, ordered without a clear indication.
- Anxiety in patients who now carry a diagnosis, whether or not it ever affects them.
Quaternary prevention, the principle of protecting patients from unnecessary intervention, applies directly to cardiology screening. A tool that finds more disease without changing mortality has not helped anyone, and demonstrating the difference requires prospective trials with clinical endpoints.
Where artificial intelligence in healthcare stalls
Deployment fails for reasons that have little to do with the model. Hospital records systems rarely expose the data an algorithm needs in a usable form, interoperability standards remain partial, and moving output back into the clinical workflow means writing into a record system that was never designed for it. Legacy infrastructure, long procurement cycles and unclear ownership of the resulting decision slow the rest. Digital infrastructure has a role in this that no model can compensate for, and knowledge of how a department actually runs is a precondition for a successful rollout.
Clinician trust is the other half. A cardiologist may receive a recommendation through an interface that offers no basis for it, and rejecting it is the responsible choice, because liability for the error stays with the doctor. AI is not the bottleneck in cardiology today; implementation is. Explainability requirements, audit trails and education in how the models behave address that gap, and medical and nursing curricula have started to include this material. Privacy obligations add a further constraint, since patient data leaving a hospital boundary raises questions that a technical answer alone does not settle.
Artificial intelligence in cardiology beyond detection
The tools that change practice do more than classify. They propose an action, fit inside an existing routine and take work away from the clinician instead of adding an inbox to check. Triage that reorders a worklist by urgency, automated measurement that removes manual tracing, and documentation support that returns time to consultations all demonstrate value in a way a detection metric cannot.
Personalization is the direction most often promised and least often demonstrated. Matching a therapy to a patient profile is plausible in principle; showing that the matched therapy improves outcomes takes a trial. Ethical accountability frameworks matter here too, because a system that influences treatment selection needs a defined answer to who is responsible when it is wrong.
What investors look for in cardiology startups
Aegis Capital assesses medical technology on the pathway to clinical use, not on benchmark scores. A defined indication, a regulatory route, evidence generated prospectively and a plan for integration carry more weight at seed stage than an accuracy figure from a retrospective dataset. Innovation can advance quickly once a tool proves effective in daily use, and a significant part of due diligence is checking whether such evidence exists and how the team will ensure the output lands inside the record system. The fund invests up to PLN 3 million as an initial ticket and up to PLN 8 million per company across follow-on rounds.
Example: Approxima, a portfolio company of the fund, develops a transcatheter system for tricuspid regurgitation that targets the mechanical cause of the disease. It illustrates the criterion applied to any submission, including software: the technology has to end in a treatment someone can deliver.
Devices and algorithms follow different regulatory paths, and both require the same demonstration in the end. A company that moves from discovery to deployment without prospective data will meet the question later, from a payer instead of a regulator.
Prospective validation and multi-center trials
Retrospective performance is a hypothesis. Confirming it takes a prospective design, ideally across several centers, because a single-site model absorbs local patterns in equipment, coding and case mix that do not travel. Multi-center validation exposes those dependencies before deployment does.
Cost-effectiveness evidence is scarcer still. Payers ask whether a tool reduces admissions, shortens length of stay or replaces a more expensive test, and few cardiology algorithms have answered with trial data. Building that evidence is slow work, and it is the step that separates a research result from a product.
Tip: when evaluating a cardiology AI claim, check whether the study was prospective, whether it was run at more than one center, and whether the endpoint was a clinical outcome or a detection rate.
Frequently asked questions
Does AI improve diagnostic accuracy in cardiology?
In retrospective studies, frequently yes, particularly in ECG interpretation and image measurement. Accuracy under study conditions does not automatically transfer to routine practice, where data quality and workflow differ.
Can AI predict a heart attack?
Models estimate risk of adverse cardiac events from routine clinical data with useful discrimination at population level. Individual prediction remains imprecise, and a risk score is a prompt for assessment, not a diagnosis.
Are wearables with AI features reliable for heart rhythm?
They detect possible atrial fibrillation well enough to prompt a clinical check and generate false positives often enough that confirmation with a medical ECG is required before any treatment decision.
Why do hospitals adopt these tools slowly?
Integration with record systems, procurement, liability, staff training and the absence of a reimbursement code account for most of the delay. Model performance is rarely the limiting factor.
What would prove that AI improves outcomes in cardiology?
A multi-center prospective trial with mortality, hospitalization or quality of life as the endpoint, comparing care with the tool against standard care. A handful of studies now approach that design, and their results will shape the future of the field.
